Abstract Details
|
PRESENTER |
No disclosure on file |
| Carlos Lopez Gomez, PhD (Columbia University) | No disclosure on file |
| No disclosure on file | |
| No disclosure on file | |
| James J. Riviello, Jr., MD (Texas Children'S Hospital) | Dr. Riviello has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biomarin. Dr. Riviello has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for J. Kiffin Penry Foundation. An immediate family member of Dr. Riviello has received publishing royalties from a publication relating to health care. Dr. Riviello has received personal compensation in the range of $500-$4,999 for serving as a Visiting Professor with University of Utah. Dr. Riviello has received personal compensation in the range of $500-$4,999 for serving as a Visiting Professor with University of Calgary. |
| Michio Hirano, MD, FAAN (Columbia University Medical Center) | Dr. Hirano has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Modis Therapeutics (a subsidiary of Zogenix). Dr. Hirano has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Epirium Bio. Dr. Hirano has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Innovation Specialist. Dr. Hirano has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Precision Biosciences. Dr. Hirano has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Platform Q Health. Dr. Hirano has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for UCB. Dr. Hirano has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Stealth Biotherapeutics. The institution of Dr. Hirano has received research support from Modis Therapeutics (a subsidiary of Zogenix. The institution of Dr. Hirano has received research support from Cyclerion. Dr. Hirano has received research support from Reneo Pharmaceuticals. The institution of Dr. Hirano has received research support from Astellas. Dr. Hirano has received intellectual property interests from a discovery or technology relating to health care. Dr. Hirano has received intellectual property interests from a discovery or technology relating to health care. Dr. Hirano has received personal compensation in the range of $0-$499 for serving as a Study Section Reviewer with NIH. Dr. Hirano has a non-compensated relationship as a Research Advisory Board member with Muscular Dystrophy Association that is relevant to AAN interests or activities. Dr. Hirano has a non-compensated relationship as a Scientific and Medical Advisory Board member with United Mitochondrial Disease Foundation that is relevant to AAN interests or activities. Dr. Hirano has a non-compensated relationship as a Scientific Advisory Board member with Barth Syndrome Foundation that is relevant to AAN interests or activities. |
| Catarina Quinzii Hirano, MD | No disclosure on file |